Radiation Oncology Journal

  • 제34권1호
  • /
  • Pages.34-44
  • /
  • 2016
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer

  • Yu, Jeong Il (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Hee Chul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Choi, Doo Ho (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Noh, Jae Myoung (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Oh, Dongryul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Jun Su (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Chang, Ji Hyun (Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Kim, Seung Tae (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Jeeyun (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Se Hoon (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Joon Oh (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Young Suk (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lim, Ho Yeong (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kang, Won Ki (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2015.12.18
  • 심사 : 2016.03.03
  • 발행 : 2016.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: A prospective phase II trial was conducted to evaluate the effectiveness and toxicity of regional hyperthermia and whole liver irradiation (WLI) for numerous chemorefractory liver metastases from colorectal cancer. Materials and Methods: Enrolled patients had numerous chemorefractory hepatic metastases from colorectal cancer. Five sessions of hyperthermia and seven fractions of 3-gray WLI were planned. Health-related quality of life (HRQoL) was determined using the Korean version of the European Organization for Research and Treatment of Cancer quality of life questionnaire C-30 and the Functional Assessment of Cancer Therapy-Hepatobiliary version 4.0. Objective and pain response was evaluated. Results: A total of 12 patients consented to the study and the 10 who received WLI and hyperthermia were analyzed. WLI was completed as planned in nine patients and hyperthermia in eight. Pain response was partial in four patients and stable in four. Partial objective response was achieved in three patients (30.0%) and stable disease was seen in four patients at the 1-month follow-up. One patient died 1 month after treatment because of respiratory failure related to pleural metastasis progression. Other grade III or higher toxicities were detected in three patients; however, all severe toxicities were related to disease progression rather than treatment. No significant difference in HRQoL was noted at the time of assessment for patients who were available for questionnaires. Conclusion: Combined WLI and hyperthermia were well tolerated without severe treatment-related toxicity with a promising response from numerous chemorefractory hepatic metastases from colorectal cancer.

키워드

참고문헌

  1. Seo SI, Lim SB, Yoon YS, et al. Comparison of recurrence patterns between ${\leq}5$ years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol 2013;108:9-13. https://doi.org/10.1002/jso.23349
  2. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver: I. the prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969;23:198-202. https://doi.org/10.1002/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO;2-J
  3. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br J Surg 1999;86:158-69. https://doi.org/10.1046/j.1365-2168.1999.01013.x
  4. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16. https://doi.org/10.1016/S0140-6736(08)60455-9
  5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. https://doi.org/10.1056/NEJMoa032691
  6. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014;371:1609-18. https://doi.org/10.1056/NEJMoa1403108
  7. Michl M, Holtzem B, Koch J, et al. Metastatic colorectal cancer: analysis of treatment modalities and survival now and then. Dtsch Med Wochenschr 2014;139:2068-72. https://doi.org/10.1055/s-0034-1387283
  8. Cao R, Zhang S, Ma D, Hu L. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Med Oncol 2015;32:325. https://doi.org/10.1007/s12032-014-0325-9
  9. Cromheecke M, de Jong KP, Hoekstra HJ. Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 1999;25:451-63. https://doi.org/10.1053/ejso.1999.0679
  10. Schefter TE, Kavanagh BD. Radiation therapy for liver metastases. Semin Radiat Oncol 2011;21:264-70. https://doi.org/10.1016/j.semradonc.2011.05.006
  11. Hoyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys 2012;82:1047-57. https://doi.org/10.1016/j.ijrobp.2011.07.020
  12. Yeo SG, Kim DY, Kim TH, Kim SY, Hong YS, Jung KH. Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction. Radiat Oncol 2010;5:97. https://doi.org/10.1186/1748-717X-5-97
  13. Leibel SA, Pajak TF, Massullo V, et al. A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys 1987;13:1057-64. https://doi.org/10.1016/0360-3016(87)90045-9
  14. Rao W, Deng ZS, Liu J. A review of hyperthermia combined with radiotherapy/chemotherapy on malignant tumors. Crit Rev Biomed Eng 2010;38:101-16. https://doi.org/10.1615/CritRevBiomedEng.v38.i1.80
  15. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487-97. https://doi.org/10.1016/S1470-2045(02)00818-5
  16. Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys 1981;7:587-91. https://doi.org/10.1016/0360-3016(81)90370-9
  17. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965;93:200-8.
  18. Lawrence TS, Dworzanin LM, Walker-Andrews SC, et al. Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys 1991;20:555-61. https://doi.org/10.1016/0360-3016(91)90069-G
  19. Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol 2011;26 Suppl 1:213-9.
  20. Park JS, Park HC, Choi DH, et al. Prognostic and predictive value of liver volume in colorectal cancer patients with unresectable liver metastases. Radiat Oncol J 2014;32:77-83. https://doi.org/10.3857/roj.2014.32.2.77
  21. Song DY, Jones RJ, Welsh JS, et al. Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2003;57:166-71. https://doi.org/10.1016/S0360-3016(03)00508-X

피인용 문헌

  1. Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary? vol.7, pp.None, 2016, https://doi.org/10.3389/fonc.2017.00132
  2. Efficacy of Combined Regional Inductive Moderate Hyperthermia and Chemotherapy in Patients With Multiple Liver Metastases From Breast Cancer vol.17, pp.None, 2018, https://doi.org/10.1177/1533033818806003
  3. Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases vol.13, pp.9, 2019, https://doi.org/10.1080/17474124.2019.1621166